25 August 2017 - Medicines Australia notes the Government has today released their response to the Productivity Commission’s Inquiry in Intellectual Property.

We know that strong intellectual property (IP) leads to greater innovation in the pharmaceutical sector.

We’re pleased the Government does not intend to implement the detrimental recommendations made by the Productivity Commission as any changes that weaken IP in Australia could have a negative impact on the ability for all Australians to access to the latest innovative medicines. It would also diminish Australia’s competitiveness for investment in vital medical research such as clinical trials.

Read Medicines Australia press release